Objectives: Presence of the apolipoprotein E (APOE) 4 allele is a risk factor for dementia, while the 2 allele offers protection against dementia. There is also evidence for a relationship between APOE genotype and changes in cognitive function. It is not clear however, whether this relationship stems from undetected disease in persons genetically more vulnerable to dementia. This study examined whether APOE genotype was associated with either initial performance or change in performance on a range of cognitive and noncognitive tasks, after accounting for possible preclinical dementia.
Introduction
The apolipoprotein E (APOE) 4 allele is an established risk factor for dementia (e.g., 1) while, conversely, the 2 allele offers protection against the disease (e.g., 2). Metaanalyses also suggest both 4-related cognitive deficits, and 2-related cognitive benefits, in later life (3, 4) . However, there is accumulating evidence that the subclinical phase of dementia precedes eventual diagnosis by several years, even decades. For instance, histopathological work (5, 6) suggests the neuropathological markers of the disease are present in middle-age and early adulthood, while cognitive deficits have been detected up to ten years before clinical diagnosis (7) . A key question, therefore, is whether APOE genotype exerts a direct influence on cognition independently of dementia-related neuropathology as numerous studies suggest, or whether 4-related cognitive deficits represent a behavioral marker of the, as yet, undetected disease in persons genetically more vulnerable to earlier onset of dementia. It is this important question that motivates the present study.
There is already evidence that the latter may be the case. For example, longitudinal studies suggest that when future dementia is taken in to account, APOE genotype-related variation in cognitive change is minimal (8, 9) , and two recent large-scale studies suggest that the more marked cognitive decline observed in 4 carriers was probably associated with the presence of subclinical dementia-related neuropathology (10, 11) .
The present study builds upon this research and also extends the earlier work of Hofer et al. (12) , who examined the effects of APOE on cognition in the present community-based population. Using the first three measurement points from the Canberra Longitudinal Study cohort (13), Hofer and colleagues examined the effects of APOE genotype on memory, processing speed and verbal ability, which were measured as latent constructs derived from multiple cognitive tasks. They found that the 4 allele was associated with poorer initial processing speed and greater declines in both speed and memory. In a cognitively intact APOE and cognitive decline in late life 4 subsample, the effects on memory remained while the processing speed effects became nonsignificant. However, the investigators were not able to control for possible neuropathology beyond the seven year assessment period of that study. The present analysis, therefore, used all four waves of the Canberra Longitudinal Study spanning 12 years, examined a broader range of cognitive measures that were not investigated in that earlier study individually, and adjusted for potential neuropathology over the entire 12-year period. We also investigated grip strength because decreased grip strength has been identified as a strong predictor of cognitive aging (14, 15) and is associated with Alzheimer pathology and disease progression (16) .
Importantly, to test whether any effects of APOE on cognition were due to possible subclinical dementia pathology, we used broader exclusion criteria for possible dementia.
Instead of using the Canberra Interview for the Elderly, a diagnostic instrument for dementia (17) used in the earlier study, a cut-off of 24 on the Mini-Mental State Examination (18) was used to exclude participants possibly in the preclinical dementia phase during the study period. Given evidence that the 2 allele may delay dementia onset and help preserve late-life cognitive performance (19) , we additionally extended the earlier study (12) by examining the specific effects of the 2 allele on cognitive change.
Following from the earlier work, we hypothesized that the APOE 4 allele would be associated with more precipitous decline in memory performance and processing speed. A non-specific protective effect of 2 on cognitive performance was also expected. However, APOE-related associations were expected to attenuate when possible dementia was taken into account. We also predicted that the 4 allele would be associated with weaker grip strength.
More specifically, given evidence that dementia pathology has an earlier and more pronounced effect on the left cerebral hemisphere (20) , and recent evidence that children with an 2 allele are more likely to be left handed (21) , it was predicted that right-hand grip APOE and cognitive decline in late life 5 strength, controlled by the left hemisphere, would exhibit greater decline in 4 carriers than non-carriers.
Methods

Participants
The Canberra Longitudinal Study is an epidemiological survey of mental health and cognitive functioning in people aged 70 and over (13) . Eight hundred and ninety-six participants (456 men and 440 women) were recruited for the baseline assessment in 1990. All participants were initially living in the community in the cities of Canberra or Queanbeyan, Australia.
Participants were sampled from the compulsory electoral roll, with 69% responding to a letter and/or phone call (see 22 for further description of the recruitment), and the sample was 
APOE Genotype
APOE genotyping was performed using DNA extracted from buccal swabs using a modification of the method of Richards et al. (24) . Polymerase chain reaction amplification of a 234 base-pair fragment of exon 4 of the apoE gene followed by digestion with CfoI was used to determine APOE genotype. These were separated by polyacrylamide gel electrophoresis and displayed by silver staining. Of the 605 participants tested, APOE genotype was successfully determined for 600. After excluding the 10 participants who had an 2/4 genotype, the sample (n = 590) consisted of 11.0% having an 2 gene (n = 2 with 2/2; n = 63 with 2/3), 23.2% having an 4 gene (n = 127 with 3/4; n = 10 with 4/4) and the remaining 65.8% being homozygous for 3 (n = 388). (29) . To facilitate comparisons between tests, all of the cognitive and grip strength measures were standardized to a common metric, with a mean of 100 and standard deviation of 10 for the complete baseline sample.
To measure choice reaction time, participants were asked to press a button with their left or right hand depending on which of two stimulus lights were illuminated (interstimulus intervals ranged from 0.5 to 2.0 seconds) (30) , and choice reaction time was measured as the mean response time over 20 trials. Grip strength was taken using a Smedley hand dynamometer which measures the force exerted in kilograms (30) . Measurements were taken for both right and left hands.
The Mini-Mental State Examination (MMSE: 18), scored out of 30, was used to screen for possible preclinical dementia. Following consideration of the broader literature (31, 32) , participants with MMSE scores ≤ 24 at any assessment were excluded to assess whether any effects of APOE on cognitive performance were attributable to possible dementia. Norms for the MMSE indicate sensitivity of 95% and specificity of 82% for detecting Alzheimer's Disease at this cut point in community-based individuals who are 80 years or older with nine or more years of education (most participants in the present study were in this category by the second wave) (33) .
Additional control variables included in each model were age, gender and years of education. Years of education were assessed using a single self-report item.
Analysis Latent growth models estimating the level (intercept) and slope of performance on each of the eight outcome measures were run. Latent growth models are a class of structural equation models that represent individual level data in terms of an initial level of performance APOE and cognitive decline in late life 8 latent variable or factor (level), a rate of change factor (slope), and error (residual) parameters (12, 34) . These structures are analogous to random intercept and slope terms in mixed models. However, latent growth modeling uses a multivariate approach, such that an outcome variable measured at four occasions gives rise to a four-variate outcome vector (35) . Like mixed models, latent growth models accommodate missing data, appropriately accommodate unequal numbers of individual observations, account for dependencies among observations within individuals, and account for individual differences in the rates of cognitive decline (36) .
Separate models were used to assess the role of APOE genotype on each of the outcome variables. In order to delineate and maximize allelic influence while retaining statistical power, the genotype combinations used in the models were as follows: 2 = 2/2+ 2/3; 3 = 3/3; 4 = 3/4+ 4/4. To assess all possible genotype comparisons, the models were run using 3 as the reference category, then repeated with 2 as the reference category.
These models were each estimated twice: once with all participants and once excluding participants with possible preclinical dementia (MMSE ≤ 24 at any assessment). Mplus version 6 was used to estimate the latent growth models which incorporated all available data under the missing at random assumption. To illustrate the effects found in the models, mixed model repeated measures analyses of variance were used to estimate cognitive performance over time, adjusting for age, gender, education and genotype. Finally, a logistic regression analysis was used to examine baseline predictors of having MMSE ≤ 24 at any time point.
PASW version 18 was used to estimate both the mixed effects models and logistic regression model.
Results
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Individuals in the analysis sample were an average age of 76.2 years at the first assessment (SD = 4.7, range = 70-93 years), and had mean 11.5 years of education (SD = 2.6). Due to the gender stratification, the sample was 49.0% men and 51.0% women. The analysis sample was significantly younger (76.2 vs. 77.2 years; F 1,894 = 9.29, p = 0.002) and better educated (11.5 vs. 11.0 years; F 1,892 = 7.45, p = 0.006) than the full sample, but did not differ in gender distribution ( Table 1 , both overall and by APOE genotype group. As indicated in the table, there were no differences across genotype groups as assessed at the initial assessment, with the exception of word recognition where 4 carriers performed significantly worse than 2 and 3 carriers. There was also some indication of poorer performance on episodic memory and MMSE in 4 carriers compared to 2 and 3 carriers, although the differences were not significant (p = 0.07). Mixed effects models indicated that performance on all of the outcomes declined significantly over time. Adjusted for age, gender, education and APOE, the effect of time was significant at p< 0.001 for all outcomes (F 3, 202-370 range: 11.1 -226.2).
In Table 2 , the latent growth model shows that the rate of decline in processing speed Importantly however, after excluding participants (n = 125) with possible preclinical dementia (i.e., persons with MMSE score ≤ 24 at any time point), the estimated genotype effects were greatly attenuated such that none of the original effects remained significant (Table 3) . Participants who met this criterion performed significantly more poorly on all of the cognitive tests administered at the second assessment, scoring one SD lower on SLMT, word recognition, face recognition and episodic memory (t 559-570 = 8.04-11.33, p < 0.001 for all), suggesting some indication of cognitive deficit. The genotype distribution in this analysis was significantly different to the analysis without the exclusion. Notably, a greater proportion of 4 carriers had low MMSE scores ( 2: n = 56 included/14% excluded, 3: n = 313 included/19% excluded, 4: n = 96 included/30% excluded; 2 = 9.2, p = 0.01). Nevertheless, the analysis had sufficient power to detect small differences between the 3 and 4 groups (conservatively assuming n = 96 per group, the power to detect an effect size of 0.2 between group effects was 0.93). The attenuation is illustrated in Figure 2 which shows the word recognition effect for those participants who did not have MMSE ≤24 at any time point. The values in this figure were estimated in the same way as those in Figure 1 . The attenuation of the APOE effect can be seen in the overlap between the six groups. Also of note is that the slopes of all groups in Figure 2 appear to be relatively flat, suggesting much of the performance decline in the initial analyses was due to possible preclinical dementia as APOE and cognitive decline in late life 11 opposed to age-based effects. Note that no participants with the 4 genotype in the 80s group remained by the fourth wave after excluding for MMSE ≤ 24, a result specific to the present cohort.
To The findings build upon earlier work on this dataset (12) by extending the analysis period to 12 years, examining a broader range of cognitive and non-cognitive variables, and using broader exclusion criteria for possible dementia. The findings have some important implications. First, they suggest that 4-related cognitive decline in old age is associated with the preclinical phase of, as yet, undetected dementia rather than an independent effect of APOE genotype on cognition. Although we did not formally assess clinical dementia, when persons with low MMSE scores were removed from the sample, APOE-related effects disappeared. As low MMSE scores are associated with a higher likelihood of dementia (31, 32) , this finding is consistent with several other studies (e.g., 8, 9, 10) that demonstrate null 4-related effects when future dementia is controlled for. Given accumulating evidence that the subclinical phase of the disease extends years, and perhaps decades, ahead of the eventual clinical manifestations, the findings support the view that both APOE genotype and neuropsychological assessment could be taken into account in procedures for the early detection of dementia.
It also appears that the protective effect of the 2 allele may reflect the hemispheric specificity of incipient neuropathology. As we expected, an APOE effect was detected for grip strength in the right hand. This prediction was made because it is now well documented APOE and cognitive decline in late life 13 that brain aging and dementia-related pathology affect the left hemisphere earlier and more strongly than the right (20) . Since the left hemisphere controls the right hand, deficits in grip strength would be expected first in the right hand. While we detected a protective effect for the 2 relative to the 3 allele for right hand grip strength, what is surprising is that we did not find an association between weaker grip strength and the 4 allele. This suggests a protective effect of the 2 allele against neuropathology, particularly since this disappeared in analyses that excluded persons with low MMSE scores.
A major concern in any study where significant effects disappear when participants are removed from the analyses is that reducing sample size affected statistical power. In the present context, this raises the question of whether our null results in the repeated analyses simply reflect a Type II error. We are confident that this was not the case, as a conservative post hoc power analysis found 93% power to detect an effect size of 0.2 between the 3 and 4 carriers. However, it is important to note that in our repeat analyses significantly more 4 carriers were removed from the sample due to low MMSE scores. As 4 carriers are genetically more vulnerable to earlier onset of dementia, this finding is consistent with the possibility that those excluded persons were more likely to be in the subclinical phase of the disease.
The study does possess several limitations that we should acknowledge. First, although we removed persons with low MMSE scores due to the higher likelihood that they may be experiencing dementia-related neuropathology, we were unable to confirm diagnosis.
However, the MMSE criterion used in the present study drew upon work elsewhere (31, 32) , and was broader in excluding possible dementia cases than the Canberra Interview for the Elderly criteria which in the earlier study detected only 30 dementia cases at any time point (compared to n = 125 with MMSE ≤24 here). Although the MMSE is not a conclusive executive function and episodic memory, both shown to be sensitive to 4-related effects (3, 4) , it remains possible that our battery was insufficiently broad to capture the effects of interest. Future work from our laboratories will address this issue using other datasets.
Fourth, the available data were not sufficient for investigating quadratic or exponential changes in cognition (across four waves) and did not provide sufficient numbers of e2/2 and e4/4 homozygotes to separate homozygotes from heterozygotes. Finally, APOE genotyping took place at Wave 2 of the study, and therefore excluded those who died or withdrew after baseline assessment. This may have led to a genetically more homogeneous sample resulting in more conservative estimates.
To conclude, this study adds to evidence that APOE 4-related cognitive decline in older community-dwelling populations is due to a higher likelihood of, as yet, undetected dementia among 4 carriers. Moreover, the findings also suggest a protective effect for persons in possession of the 2 allele. It is important that further longitudinal work is undertaken in community-based populations to confirm these findings. If the more precipitous cognitive decline commonly reported among older 4 carriers is due to a greater proportion of those persons eventually becoming demented, it suggests that both APOE and cognitive decline in late life 15 neuropsychological testing and APOE genotyping could inform early detection programs for dementia in early old age. 
